Search

The article presents case study of a 57-year-old man who was suspected with pyoderma gangrenosum (PG) of the right leg, diagnosed with central necrosis and ulceration. It mentions the laboratory tests which revealed anaemia and thrombocytopenia with myelocytosis along with diagnosis necrotizing fasciitis followed by surgical debridement. It also discusses the efficacy of Cyclosporine and anti-TNF alpha infliximab using systemic corticosteroid technique.

A letter to the editor is presented which describes the successful and well-tolerated treatment of diffuse genital warts with intravenous (IV) cidofovir.

The article presents a case study of a 50 year old man with a pigmented lesion of the anterior aspect of neck of one year duration. Topics discussed include diagnosis of lichen sclerosus (LS) mimicking a halo-naevus comedonicus in an adult patient being made, histology of LS showing atrophy of epidermis with vacuolar degeneration of basal layer and orthohyperkeratosis of the stratum corneum and considering of photodynamic therapy or surgery as treatment.

Reports on the isolation and characterization of four polymorphic microsatellite loci in univoltine earwig, Forficula auricularia. Primer sequences; Core repeat; Allele size range; Number of tested individuals; Consequences of different dispersal modes on population structure; Parent-offspring relationships; Breeding systems.

Idiopathic multicentric Castleman disease (iMCD) is a non-clonal inflammatory lymphoproliferative disorder of unknown origin. Recently, TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) emerged as a singular variant of iMCD in Asia and was associated with a severe course and a poor outcome. The present study describes the first large Western cohort of TAFRO syndrome patients (n = 25) meeting the All Japan TAFRO Syndrome Research Group diagnostic criteria. Characteristics of TAFRO patients were compared to iMCD-not otherwise specified (iMCD-NOS) patients used as a control group (n = 43). Our results show that despite baseline characteristics in accordance with previously reported series, Western TAFRO syndrome patients do not appear to present with a worse outcome than iMCD-NOS patients. There were no significant differences between the two groups regarding treatment choice, response to rituximab (71% vs. 67%) or tocilizumab (69% vs. 91%) in TAFRO and iMCD-NOS, respectively. The two-year overall survival was above 95% in both groups. Limits of inclusion and exclusion criteria for TAFRO definition are also discussed. Our findings raise the question of the singularity of the TAFRO entity in Western countries. The data should promote further research using unsupervised models to identify markers of disease severity in Western cohorts of iMCD patients., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)

Human immunodeficiency virus (HIV)-associated primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma with poor prognosis. Lymphoma cells are always infected with human herpesvirus-8 (HHV-8) and in most cases coinfected with Epstein-Barr virus. In classic presentation, PEL is characterized by body cavity effusions with or without mass lesions. A variant with only extracavitary localization has also been described. We report on a large single-center series of patients with PEL in the era of combined antiretroviral therapy (cART). The main objective was to compare the characteristics and the outcome of patients with classic (n = 34) and extracavitary (n = 17) variant PEL. At PEL diagnosis, no major difference was observed between the two groups in terms of demographic and HIV characteristics. Extracavitary localizations were exclusively nodal in six patients and involved various organs in 11 patients. Another HHV-8-associated disease was observed in 31 patients, Kaposi sarcoma in 25, and multicentric Castleman disease in 18 patients, without difference between the two groups. Thirty-two patients were treated with CHOP associated with high-dose methotrexate, 13 were treated with CHOP-derived regimen alone, and six patients received low-dose/no chemotherapy. Complete remission was achieved in 21 (62%) and seven (41%) patients of the classic and extracavitary groups, respectively. The median overall survival (OS) was 10.2 months. Despite a higher disease-free survival in the extracavitary group, there was no difference in OS between the two variants. Based on this series, characteristics of classic and extracavitary variants were very close. Although prognosis of PEL remains very severe in cART era, the median survival compares favorably with earlier series., (© 2015 Wiley Periodicals, Inc.)